To the full analysis
Dermapharm Holding stock: growth
DMP.DEDermapharm Holding reported $1.29B in revenue for fiscal 2025, down 1.3% on the prior year, up 8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
10.4%
per year from 2014 to 2025, per share 10.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
16.6%
per year from 2014 to 2025, per share 16.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2014 | |
|---|---|---|---|
| Revenue | 8.0% | 11.7% | 10.4% |
| Revenue per share | 8.0% | 11.7% | 10.4% |
| Earnings | 9.1% | 26.4% | no data |
| Earnings per share | 9.1% | 26.2% | no data |
| Free cash flow | 9.1% | 18.5% | 16.6% |
| Free cash flow per share | 9.1% | 18.5% | 16.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $433.64M | −$67.59K | $28.62M |
| 2015 | $426.44M | $14.07M | $28.19M |
| 2016 | $492.53M | $18.64M | $65.4M |
| 2017 | $517.61M | $86.15M | $13.32M |
| 2018 | $634.3M | $83.47M | $147.55M |
| 2019 | $776.64M | $85.54M | $60.03M |
| 2020 | $879.64M | $95.1M | $100.06M |
| 2021 | $1.04B | $232.24M | $209.61M |
| 2022 | $1.14B | $148.75M | $276.49M |
| 2023 | $1.26B | $69.11M | $197.11M |
| 2024 | $1.31B | $126.09M | $180.78M |
| 2025 | $1.29B | $146.73M | $154.46M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 17 Jul 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.